Physician profile
Samuel I Chu
NPI 1245322700
$9,230.46
in general payments reported to CMS, 2019-2025
33 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $650 · 2021: $1,413 · 2022: $1,671 · 2023: $1,491 · 2024: $1,309 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $51.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,286.92 |
| Education | $51.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,972.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,312.79 | 2019-2025 | Linzess, Creon, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $859.17 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $857.46 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $723.11 | 2019-2024 | Xarelto |
| Amgen INC. | $390.30 | 2019-2025 | Repatha, Evenity, Prolia |
| Gilead Sciences, INC. | $374.32 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $328.77 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $324.07 | 2019-2021 | |
| Glaxosmithkline, LLC. | $303.77 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Lilly USA, LLC | $253.96 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $210.19 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $205.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $179.74 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $174.11 | 2021-2025 | Zoryve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $144.52 | 2025 | |
| Sanofi-Aventis U.S. LLC | $93.99 | 2019-2025 | |
| Lundbeck LLC | $86.77 | 2023-2024 | Rexulti |
| Dexcom, INC. | $79.54 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $42.21 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bausch Health US, LLC | $39.34 | 2019-2021 | |
| Teleflex LLC | $36.87 | 2024 | Urolift |
| Teva Pharmaceuticals USA, INC. | $27.33 | 2022 | |
| Allergan, INC. | $27.29 | 2019 | |
| Mannkind Corporation | $26.86 | 2021 | |
| Nestle Healthcare Nutrition INC. | $24.79 | 2022 | |
| Eisai INC. | $24.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.02 | 2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $19.81 | 2024 | Horizant |
| Biohaven Pharmaceuticals, INC. | $16.02 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.61 | 2024 | Quviviq |
| Seqirus USA INC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.